Dear Editor,
Teledermatology represented one of the most important tools during the COVID‐19 pandemic, allowing physicians to continue caring for patients while avoiding the risk of infection for both. 1 , 2 To overcome restrictions on face‐to‐face (F2F) visits during the pandemic, we expanded our teledermatology services for patients, increasing the number of consultations through these services and also increasing the type of services available for patients. 3 In particular, we used video‐call and phone‐call consultations and email support for patients, to ensure continuity of care as much as possible, especially for patients with chronic skin diseases requiring long‐term treatment and follow‐up, such as psoriasis or hidradenitis suppurativa. 4 , 5 We report our findings using a questionnaire‐based study evaluating patient satisfaction about the use of teledermatology.
An eight‐item questionnaire was created to investigate patient opinion of our teledermatology services. Patients consulting at our clinic through teledermatology services were consecutively included in the study. Each enrolled patient was asked to anonymously complete a questionnaire after the consultation.
In total, 265 patients were consecutively enrolled in the study. However, 13 were excluded from the study due to incomplete questionnaires. Hence, a total of 252 fully completed questionnaires were assessed (Table 1).
Table 1.
Questionnaire | Type of consultation | ||
---|---|---|---|
Video | Phone | ||
Clinical and demographic data | |||
Gender | |||
Male | 53 | 69 | |
Female | 47 | 83 | |
Age (years) | |||
18–35 | 30 | 70 | |
36–45 | 35 | 35 | |
46–65 | 45 | 25 | |
> 65 | 3 | 24 | |
Condition | |||
Acne | 98 | 43 | |
Psoriasis | 55 | 50 | |
Hidradenitis suppurativa | 30 | 13 | |
Alopecia (any type) | 25 | 18 | |
Other | 23 | 19 | |
Patient satisfaction | |||
Rate your satisfaction for the teledermatology service (1–3unsatisfied; 4–6 satisfied; 7–10 very satisfied) | |||
1–3 | 47 | 65 | |
4–6 | 115 | 80 | |
7–10 | 150 | 157 | |
Would you choose teledermatology for future consultations? | |||
Yes | 168 | 198 | |
No | 114 | 54 | |
Do you consider a teledermatology consultation as satisfactory as aface‐to‐face visit? | |||
Yes | 52 | 40 | |
No | 200 | 212 | |
Do you have any concerns about teledermatology? | |||
Yes | 178 | 182 | |
No | 44 | 40 | |
If you answered ‘Yes’ to the previous question, what concerns do you have? | |||
Privacy (photo, video) | 62 | 40 | |
I feel uncomfortable with this technology | 32 | 38 | |
I feel uncomfortable receiving a prescription by teledermatology | 22 | 34 | |
I prefer a face‐to‐face visit | 62 | 70 |
Interestingly, we found high levels of satisfaction using both video‐ and phone‐based teledermatology services. Patients using video‐based consultations were more (but not significantly) satisfied than phone‐based consultations, reporting that they will use this service in the future. Another interesting finding was that most of patients reporting satisfaction with the teledermatology services, both video‐ and phone‐based consultations, were younger patients with acne or chronic skin diseases (psoriasis and hidradenitis suppurativa), whereas older patients reported that they would prefer an F2F visit. 5 , 6
However, despite the high satisfaction level, most of the interviewed patients did not consider a teledermatology consultation as satisfactory as an F2F visit. This may be influenced by the platform used, difficulties that patients (especially older patients) may have using such technology, and privacy concerns.
Teledermatology had a central role during the COVID‐19 pandemic, which led to marked development of this type of service, resulting in widespread use and high satisfaction rates reported by both patients and physicians.
However, despite the widespread escalation of this technology, there are still major difficulties, such as privacy concerns and medicolegal issues, as an official and widely accepted form of informed consent during such consultations is lacking, as well as the absence of specified and safe online teledermatology platforms, which may represent obstacles to the further utilization and application of this useful service. Hence, official guidelines and recommendations are urgently needed to improve these services and increase the safety of and satisfaction with teledermatology consultations for patients and dermatologists.
Conflict of interest: The authors declare that they have no conflicts of interest.
Funding: None.
Ethics statement: Ethics approval and informed consent not applicable.
Data availability: Not applicable.
References
- 1. Schroedl LM, Duan GY, De Luzuriaga AR. Teledermatology during COVID‐19: a comparison of video and telephone visits with patient‐uploaded images at an urban academic medical center. Dermatol Online J 2022; 28. doi: 10.5070/D328157057 [DOI] [PubMed] [Google Scholar]
- 2. Villani A, Megna M, Scalvenzi M et al. Teledermatology and chronic skin diseases: real life experience in a Southern Italian Dermatologic Centre. Dermatol Ther 2020; 33: e13839. [DOI] [PubMed] [Google Scholar]
- 3. Marasca C, Ruggiero A, Megna M et al. Biologics for patients affected by hidradenitis suppurativa in the COVID‐19 era: data from a referral center of Southern Italy. J Dermatolog Treat 2022; 33: 592. [DOI] [PubMed] [Google Scholar]
- 4. Armstrong AW, Chambers CJ, Maverakis E et al. Effectiveness of online vs in‐person care for adults with psoriasis: a randomized clinical trial. JAMA Netw Open 2018; 1: e183062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Napolitano M, Patruno C, Ruggiero A et al. Safety of dupilumab in atopic patients during COVID‐19 outbreak. J Dermatolog Treat 2022; 33: 600–1. [DOI] [PubMed] [Google Scholar]
- 6. Marasca C, Ruggiero A, Napolitano M et al. May COVID‐19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses 2020; 143: 109853. [DOI] [PMC free article] [PubMed] [Google Scholar]